Interview: Nobel chemistry laureate Jennifer Doudna on the promise and peril of the genetic editing revolution
By John Mecklin,
Bulletin of the Atomic Scientists
| 12. 07. 2020
Just weeks after I interviewed her this September, UC Berkeley professor Jennifer Doudna and her colleague Emmanuelle Charpentier were jointly awarded the Nobel Prize in Chemistry for their discovery of the CRISPR/Cas9 genetic editing tool. An acronym for Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR sequences were found in bacteria, where they protect against viruses by chopping them into pieces. Doudna and Charpentier devised a way to reprogram these genetic scissors, so they could be directed to cut any DNA molecule at a predetermined site.
The CRISPR/Cas9 editing tool has greatly reduced the amount of time needed to edit genes and is now in use by researchers around the world. “There is enormous power in this genetic tool, which affects us all. It has not only revolutionized basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments,” Claes Gustafsson, chair of the Nobel Committee for Chemistry, said in a press release accompanying the Nobel Prize announcement.
The positive potential of CRISPR editing tools is indeed breathtaking. “This tool has contributed to many important discoveries...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...